Last reviewed · How we verify
blood drawn
At a glance
| Generic name | blood drawn |
|---|---|
| Sponsor | ANRS, Emerging Infectious Diseases |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Disorders of the Acute Phase Response Following Trauma and Invasive Surgery (NA)
- Individualized Precision Isavuconazole Therapy Guided by PK/PD Principles for the Geriatric Population
- Individualized Precision Therapy With Ceftazidime and Avibactam Guided by PK/PD in Geriatric Populations
- Correlation Vitamin D Level to Endocrine Autoimmune Toxicity Due to Immune Checkpoint Inhibitors
- Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer (NA)
- Cellular and Molecular Characterization of the Immune Response in Healthy NIH Employees atBaseline, and After Immunization With the H1N1 or Seasonal Influenza Vaccines
- A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) (NA)
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- blood drawn CI brief — competitive landscape report
- blood drawn updates RSS · CI watch RSS
- ANRS, Emerging Infectious Diseases portfolio CI